CEO | President

Ric Stanulis, PhD, DABT

Dr. Ric Stanulis is the President and CEO of Akkeri. He is a board-certified toxicologist with over 25 years of nonclinical drug development experience. Since 2017, Ric has been a nonclinical consultant providing strategic advice on scientific and regulatory issues in drug development, working with clients of diverse resources and needs across the U.S., Europe, and Asia.

Ric received his PhD in Pharmacology and Toxicology from the Medical College of Virginia/Virginia Commonwealth University and entered the industry as a Study Director for a CRO. He then worked for several biotech and small pharmaceutical companies, primarily establishing and overseeing nonclinical safety assessment functions. As a result, Ric understands the needs, complexities, and pitfalls faced by early-stage biotech companies.

He provides full nonclinical program support, with expertise in toxicology program design and study conduct, regulatory document and meeting preparation, gap analysis and due diligence, and issue resolution for challenges that inevitably arise. Ric has experience with a variety of development programs, including small and large molecules, as well as gene therapy, at all stages of development, across diverse therapeutic areas, and with various routes of administration. He routinely interacts with regulatory agencies and has directly contributed to the successful filing of numerous INDs/CTAs and NDAs/BLAs.

Ric is an active member of the American College of Toxicology, the Society of Toxicology, and the Safety Pharmacology Society.